🫀 Low VTE and CV Event Rates in UC Patients Initiating Advanced Therapy

🔥 Main in 3 points:

• In a cohort of 300 ulcerative colitis (UC) outpatients starting advanced therapies, real-world baseline thromboembolic (VTE) and cardiovascular (CV) risk was generally low.
• Over a median 27 months (683 person-years), only 2 VTE events (both on ustekinumab) and 2 CV events (angina on vedolizumab, retinal ischemia on adalimumab) were recorded, for an overall incidence rate of 0.59 per 100 PY.
• Most patients had 0–1 VTE risk factor; CV risk increased with age but remained low-to-moderate overall in non-elderly.

🧪 Context:

Cross-sectional + prospective single center study monitoring consecutive UC patients initiating advanced therapies between 2020–2023. Baseline risk factors, activity levels, and real-world incidence captured; events tracked for nearly 2.5 years.

📍 Practical significance:

• Most UC patients starting advanced therapies (including vedolizumab) have a low baseline risk for VTE or CV events.
• Vigilant risk assessment remains crucial in the elderly or those with comorbidities, but real-world event rates are low.
• Findings suggest current concerns about intrinsic thrombotic or CV risk of advanced UC therapies do not generalise, supporting therapy selection aligned to clinical need.

🔗 Source:

PubMed

DOI

🫀 Which Crohn’s Patients Benefit Most from Vedolizumab? Insights from Real-World Data

✅ Study answer:

• Among 264 Crohn's disease (CD) patients, rates of steroid-free remission at Week 26 and Week 52 were 46.6% and 38.6%, respectively; vedolizumab was well tolerated (4.2% adverse reactions, no serious events).
• Best response: bio-naïve, no active intestinal fistula, mild baseline activity (CDAI ≤220, CRP ≤10 mg/L).
• A practical nomogram using these variables accurately predicted Week 26 (AUC 0.83) and Week 52 (AUC 0.70) steroid-free remission.

📍 How to apply:

• Prioritise vedolizumab for bio-naïve CD patients, without fistulising disease and with lower inflammatory markers.
• Consider using clinical tools (nomogram, CDAI, CRP) to predict remission chance.
• Ongoing tolerance and low AE rates support vedolizumab safety in diverse practice.

🔗 Source:

PubMed

DOI